Literature DB >> 18504285

Treating infertility in autoimmune patients.

M Costa1, D Colia.   

Abstract

Fertility in patients with SLE and other systemic autoimmune disease is usually unaltered. However, fertility may be impaired by anovulation during episodes of active disease or chronic renal failure, administration of NSAIDs, high dose of corticosteroids and cyclophosphamide. Early pregnancy loss occurs in SLE patients with aPLs. An association of autoimmune disease with infertility has been suggested, but the studies are not conclusive. Ovulation stimulation as a fertility treatment could theoretically induce SLE. However, two recent studies did not find previous use of fertility drugs and in vitro fertilization to be more frequent in the history of SLE patients when compared with controls. Patients with SLE or primary APS, who are undergoing infertility treatment, could be at risk of flare or thrombosis. In the past 10 yrs, many reports have been published regarding the risk of lupus exacerbation associated with controlled ovarian hyperstimulation; not all found excess risk. At the moment we do not have any prospective study in this field. A trend towards a worse prognosis in cases of SLE patients undergoing assisted reproductive techniques (ARTs) for pregnancy rate, live-birth rate and maternal complications can be seen. If hormonal ovarian stimulation is useful, well-advised management would administer a low effective gonadotropin dose in a patient whose disease has been silent preferably for at least 6 months. Further data are needed to establish safety and efficacy of ART in SLE patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18504285     DOI: 10.1093/rheumatology/ken156

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Acute immunomodulatory changes during controlled ovarian stimulation: evidence from the first trial investigating the short-term effects of estradiol on biomarkers and B cells involved in autoimmunity.

Authors:  Anna Ghirardello; Salvatore Gizzo; Marco Noventa; Michela Quaranta; Amerigo Vitagliano; Nicoletta Gallo; Giorgia Pantano; Marianna Beggio; Chiara Cosma; Michele Gangemi; Mario Plebani; Andrea Doria
Journal:  J Assist Reprod Genet       Date:  2015-10-14       Impact factor: 3.412

2.  Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve.

Authors:  Clara Di Mario; Luca Petricca; Maria Rita Gigante; Angelina Barini; Antonella Barini; Valentina Varriano; Annamaria Paglionico; Paola Cattani; Gianfranco Ferraccioli; Barbara Tolusso; Elisa Gremese
Journal:  Endocrine       Date:  2018-10-15       Impact factor: 3.633

Review 3.  Xenobiotic effects on ovarian preantral follicles.

Authors:  Connie J Mark-Kappeler; Patricia B Hoyer; Patrick J Devine
Journal:  Biol Reprod       Date:  2011-06-22       Impact factor: 4.285

4.  Clinical practice guideline on pregnancy and renal disease.

Authors:  Kate Wiles; Lucy Chappell; Katherine Clark; Louise Elman; Matt Hall; Liz Lightstone; Germin Mohamed; Durba Mukherjee; Catherine Nelson-Piercy; Philip Webster; Rebecca Whybrow; Kate Bramham
Journal:  BMC Nephrol       Date:  2019-10-31       Impact factor: 2.388

Review 5.  Managing pregnancy in inflammatory rheumatological diseases.

Authors:  Varsha Jain; Caroline Gordon
Journal:  Arthritis Res Ther       Date:  2011-02-25       Impact factor: 5.156

Review 6.  Glomerular Disease in Women.

Authors:  Kate Wiles; Liz Lightstone
Journal:  Kidney Int Rep       Date:  2018-02-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.